Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595699 · ClinicalTrials.gov registry record · Phase 4
Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy
A Phase 4 study of Major Depression and Temporal Lobe Epilepsy, sponsored by Conrad, Erich J., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00595699 is a Phase 4 study of Major Depression and Temporal Lobe Epilepsy that has completed, run by Conrad, Erich J., M.D.. The registered enrollment target is 8 participants, below the 327-participant average among 28 other Major Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00595699, a Phase 4 study of Major Depression and Temporal Lobe Epilepsy, has completed, sponsored by Conrad, Erich J., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.
Conditions Studied
Interventions
- DRUG placebo
- DRUG escitalopram
Study Locations (1)
Louisiana
- LSU Anxiety and Mood Disorders Clinic - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595699
The ClinicalTrials.gov registry entry for NCT00595699 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 28 other Major Depression trials with a reported enrollment target (98% lower). The listed sponsor is Conrad, Erich J., M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00595699 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT00595699 about?
NCT00595699 is a clinical study titled "Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy". This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram ...
What is the current status of trial NCT00595699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2006-11. Estimated completion is 2009-12.
What conditions does trial NCT00595699 study?
This clinical trial studies the following conditions: Major Depression, Temporal Lobe Epilepsy.
What interventions are being tested in trial NCT00595699?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG).
Who is sponsoring clinical trial NCT00595699?
This trial is sponsored by Conrad, Erich J., M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00595699 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.